Latency
发表于 2025-3-26 23:32:57
Dirichlet and Polya tree process,subsequent course (Kurtz et al. 1988 a). The purpose of this paper is to analyze the development of breast recurrence as a function of time, as well as to study the prognosis following treatment of local failure.
Mundane
发表于 2025-3-27 04:28:44
Inference for Location Parameter,n of patients whose tumors are more responsive to a given treatment (e.g. patients with estrogen-receptor(ER)-positive tumors, who are receiving adjuvant endocrine therapy) (Ludwig Breast Cancer Study Group 1984). The use of sequential non-cross-resistant combinations also appears to enhance effectiveness (Perloff et al. 1986).
催眠
发表于 2025-3-27 09:01:44
http://reply.papertrans.cn/15/1450/144982/144982_33.png
Meditative
发表于 2025-3-27 11:09:33
http://reply.papertrans.cn/15/1450/144982/144982_34.png
单独
发表于 2025-3-27 17:21:17
http://reply.papertrans.cn/15/1450/144982/144982_35.png
中世纪
发表于 2025-3-27 20:03:46
Dirichlet and Polya tree process,reasing doses through a multilog cell kill model. In this regard, the alkylating agents more closely resemble radiotherapy. The lack of cross-resistance among the alkylating agents in both in vitro and in vivo models has important implications for clinical treatment strategies (Frei et al. 1985; Frei et al., in press; Teicher et al. 1986).
锡箔纸
发表于 2025-3-28 00:18:58
http://reply.papertrans.cn/15/1450/144982/144982_37.png
Lucubrate
发表于 2025-3-28 02:41:26
0080-0015in this disease, the benefits of therapy are relatively mod est, the availability and interpretation of the data from trials be comes an issue of primary importance. The effects of present treat ment are in fact such that more patients relapse despite therapy than are estimated to benefit from i
考博
发表于 2025-3-28 08:30:31
http://reply.papertrans.cn/15/1450/144982/144982_39.png
fluffy
发表于 2025-3-28 11:14:12
Inference for Location Parameter,research. There is no question that such a development, if proven correct, will result in very significant practical alterations of the orthodox management of breast cancer. Therefore, before its full implementation, rigorous testing in clinical trials will be required.